S4.2.2.2-9. Larsen TB, Skj th F, Nielsen PB, et al. Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study. BMJ. 2016;353:i3189. S4.2.2.2-10. Lip GYH, Keshishian A, Kamble S, et al. Real-world comparison of major bleeding risk among non-valvular atrial fibrillation patients initi- ated on apixaban, dabigatran, rivaroxaban, or warfarin. A propensity score matched analysis. Thromb Haemost. 2016;116:975 86. S4.2.2.2-11. Noseworthy PA, Yao X, Abraham NS, et al. Direct comparison of dabigatran, rivaroxaban, and apixaban for effectiveness and safety in nonvalvular atrial fibrillation. Chest. 2016;150:1302 12. S4.2.2.2-12. Yao X, Abraham NS, Sangaralingham LR, et al. Effectiveness and safety of dabigatran, rivaroxaban, and apixaban versus warfarin in nonvalvular atrial fibrillation. J Am Heart Assoc. 2016;5:e003725. S4.2.2.2-13. Ntaios G, Papavasileiou V, Makaritsis K, et al. Real-world setting comparison of nonvitamin-K antagonist oral anticoagulants versus vitamin-K antagonists for stroke prevention in atrial fibrillation: a systematic review and meta-analysis. Stroke. 2017;48:2494 503. S4.2.2.2-14. Bai Y, Shi X-B, Ma C-S, et al. Meta-analysis of effectiveness and safety of oral anticoagulants in atrial fibrillation with focus on apixaban. Am J Cardiol. 2017;120:1689 95. S4.2.2.2-15. Calkins H, Willems S, Gerstenfeld EP, et al. Uninterrupted dabiga- tran versus warfarin for ablation in atrial fibrillation. N Engl J Med. 2017;376:1627 36. S4.2.2.2-16. Yao X, Tangri N, Gersh BJ, et al. Renal outcomes in anticoagulated patients with atrial fibrillation. J Am Coll Cardiol. 2017;70:2621 32. S4.2.2.2-17. Lau WCY, Chan EW, Cheung C-L, et al. Association between dabi- gatran vs warfarin and risk of osteoporotic fractures among patients with nonvalvular atrial fibrillation. JAMA. 2017;317:1151 8. S4.2.2.2-18. Kent AP, Brueckmann M, Fraessdorf M, et al. Concomitant oral anticoagulant and nonsteroidal anti-inflammatory drug therapy in patients with atrial fibrillation. J Am Coll Cardiol. 2018;72:255 67. 4.3. Interruption and Bridging Anticoagulation S4.3-1. 